Lab discovery could allow for heparin produced by cell lines

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/4ndrei)
(Image: Getty/4ndrei)

Related tags Heparin Cell lines

Researchers from UC San Diego identify a critical gene in the heparin biosynthesis process, which could pave the way for future industrial production.

Heparin is a widely-used anti-coagulant and is currently produced through extraction from pig intestines – though this means that production can be impacted by external factors, such as the spread of swine flu.

Last year​, the US Food and Drug Administration had to issue a statement that supplies of heparin were not impacted by African swine flu in China, though earlier this year The Lancet published​ an article suggesting that there were still concerns over supply.

As a result, researchers from the University of California San Diego stated that there is a need to “develop sustainable recombinant production,”​ further suggesting that they had made a ‘key discovery’ in this direction.

In particular, the researcher discovered that the gene ZNF263 is an active repressor of heparin biosynthesis throughout most cell types, while mast cells, which produce heparin, were enabled to produce the compound when the gene was suppressed.

This was managed by utilizing bioinformatic software to scan the genes encoding enzymes related to heparin production and then look for sequence elements that could be binding sites for transcription factors.

Due to this finding, the researchers suggested that cell lines currently used by industry, such as CHO cell lines, could be genetically modified to produce heparin in an industrial setting.

Further than this, researchers involved in the project stated that additional related gene regulators involved in heparin production had also been discovered and would form the basis of future studies.

Related topics Upstream Processing Cell lines

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more